Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment

被引：0
|
作者：
Van der Biji, AE
Breedveld, FC
Antoni, CE
Kalden, JR
Kary, S
Burmester, GR
Unnebrink, K
Kupper, H
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Univ Erlangen Nurnberg, Erlangen, Germany
[3] Charite Humbold Univ, Berlin, Germany
[4] Abbott GmbH Co KG, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：428 / +
页数：2
相关论文
共 50 条
  • [31] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [32] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [33] Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
    Louis Bessette
    Majed Khraishi
    Alan J. Kivitz
    Arunan Kaliyaperumal
    Rama Grantab
    Melanie Poulin-Costello
    Maya Isaila
    David Collier
    Rheumatology and Therapy, 2017, 4 : 391 - 404
  • [34] Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
    Bessette, Louis
    Khraishi, Majed
    Kivitz, Alan J.
    Kaliyaperumal, Arunan
    Grantab, Rama
    Poulin-Costello, Melanie
    Isaila, Maya
    Collier, David
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 391 - 404
  • [35] CASE REPORT OF INFLIXIMAB LEADING TO DISEASE CONTROL IN A MAN WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAD PREVIOUSLY FAILED ETANERCEPT
    Shenker, N.
    Haigh, R.
    Michell, L.
    Calin, A.
    RHEUMATOLOGY, 2003, 42 : 91 - 91
  • [36] Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
    Gholami, Ahmad
    Azizpoor, Jassem
    Aflaki, Elham
    Rezaee, Mehdi
    Keshavarz, Khosro
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [37] Adalimumab (HUMIRA®) is highly effective in treating patients with Ankylosing spondylitis (AS) with advanced spinal fusion
    Rudwaleit, Martin
    Torre-Alonso, Juan Carlos
    Spieler, Wolfgang
    Wong, Robert
    Kron, Martina
    Kary, Sonja
    Kupper, Hartmut
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S579 - S579
  • [38] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [39] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
  • [40] ETANAR - A ETANERCEPT BIOSIMILAR IS AS EFFECTIVE AS ADALIMUMAB AND INFLIXIMAB IN A COHORT OF REAL-LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Santos-Moreno, P.
    Saavedra-Martinez, G.
    Villarreal, L.
    Gomez, D.
    Bello-Gualtero, J.
    Giraldo, V.
    Martinez, P.
    Sanchez, A.
    Sanchez, M.
    Uribe, E.
    Boon, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 789 - 790
12345